Tian Guihua, Sun Yang, Liu Shuo, Li Chengyu, Chen Shiqi, Qiu Ruijin, Zhang Xiaoyu, Li Youping, Li Min, Shang Hongcai
Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu, China.
Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Front Pharmacol. 2018 Sep 5;9:1005. doi: 10.3389/fphar.2018.01005. eCollection 2018.
Cardiovascular diseases (CVDs) are the major public health problem and a leading cause of morbidity and mortality on a global basis. Wenxin Keli (WXKL), a formally classical Chinese patent medicine with obvious efficacy and favorable safety, plays a great role in the management of patients with CVDs. Accumulating evidence from various animal and cell studies has showed that WXKL could protect myocardium and anti-arrhythmia against CVDs. WXKL exhibited its cardioprotective roles by inhibiting inflammatory reaction, decreasing oxidative stress, regulating vasomotor disorders, lowering cell apoptosis, and protection against endothelial injure, myocardial ischemia, cardiac fibrosis, and cardiac hypertrophy. Besides, WXKL could effectively shorten the QRS and Q-T intervals, decrease the incidence of atrial/ventricular fibrillation and the number of ventricular tachycardia episodes, improve the severity of arrhythmias by regulating various ion channels with different potencies, mainly comprising peak sodium current (I), late sodium current (I), transient outward potassium current (I), L-type calcium current (I), and pacemaker current (I).
心血管疾病(CVDs)是主要的公共卫生问题,也是全球发病和死亡的主要原因。稳心颗粒(WXKL)是一种疗效显著且安全性良好的传统经典中成药,在心血管疾病患者的治疗中发挥着重要作用。来自各种动物和细胞研究的越来越多的证据表明,稳心颗粒可以保护心肌并对抗心血管疾病引起的心律失常。稳心颗粒通过抑制炎症反应、降低氧化应激、调节血管运动紊乱、减少细胞凋亡以及保护免受内皮损伤、心肌缺血、心脏纤维化和心脏肥大,发挥其心脏保护作用。此外,稳心颗粒可以有效缩短QRS和Q-T间期,降低心房/心室颤动的发生率和室性心动过速发作的次数,通过以不同效力调节各种离子通道,主要包括峰钠电流(I)、晚钠电流(I)、瞬时外向钾电流(I)、L型钙电流(I)和起搏电流(I),改善心律失常的严重程度。